Trials / Completed
CompletedNCT04616677
A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult Participants
An Open-Label, Single-Dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-42847922 in Adult Participants.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the pharmacokinetic of a single oral dose of JNJ-42847922 in adult participants with renal impairment compared with healthy participants with normal renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-42847922 | JNJ-42847922 tablet will be administered orally. |
Timeline
- Start date
- 2021-03-31
- Primary completion
- 2022-10-18
- Completion
- 2022-10-18
- First posted
- 2020-11-05
- Last updated
- 2025-04-27
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04616677. Inclusion in this directory is not an endorsement.